The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever

Lorenzo Calligaris, Federico Marchetti, Alberto Tommasini, Alessandro Ventura

Research output: Contribution to journalArticlepeer-review

Abstract

Colchicine is the treatment of choice in familial Mediterranean fever (FMF) for the prevention of both attacks and secondary amyloidosis. The overall nonresponder rate is about 5-10%. Anakinra is known to have good effectiveness in a severe autoinflammatory syndrome [chronic infantile neurological cutaneous and articular (CINCA) syndrome] and other recurrent hereditary periodic fevers. Pyrin-the protein involved in FMF-has a role in activating the proinflammatory cytokine interleukin (IL)-1β. We report the effectiveness of the addition of an IL-1-receptor inhibitor (anakinra) to colchicine in controlling the febrile attacks and acute phase response in an adolescent with FMF resistant to colchicine.

Original languageEnglish
Pages (from-to)695-696
Number of pages2
JournalEuropean Journal of Pediatrics
Volume167
Issue number6
DOIs
Publication statusPublished - Jun 2008

Keywords

  • Anakinra
  • Colchicine resistance
  • Familial Mediterranean fever

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever'. Together they form a unique fingerprint.

Cite this